New drug targets brain inflammation in early Alzheimer's patients
NCT ID NCT05318976
Summary
This Phase 2 study tested whether XPro1595 could help people with early Alzheimer's disease who show signs of brain inflammation. The trial involved 208 participants aged 50-85 who received either the drug or a placebo for 24 weeks. Researchers measured changes in memory, thinking skills, daily functioning, and brain health markers to see if the treatment could slow disease progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEMENTIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
INmune Bio Investigational Site
Darlinghurst, New South Wales, 2010, Australia
-
INmune Bio Investigational Site
Macquarie Park, New South Wales, 2113, Australia
-
INmune Bio Investigational Site
Adelaide, South Australia, 5011, Australia
-
INmune Bio Investigational Site
Box Hill, Victoria, 3128, Australia
-
INmune Bio Investigational Site
Carlton, Victoria, 3053, Australia
-
INmune Bio Investigational Site
Ivanhoe, Victoria, 3079, Australia
-
INmune Bio Investigational Site
Parkville, Victoria, 3050, Australia
-
INmune Bio Investigational Site
Nedlands, Western Australia, 6009, Australia
-
INmune Bio Investigational Site
Kelowna, V1Y 1Z9, Canada
-
INmune Bio Investigational Site
Ottawa, K1Z 1G3, Canada
-
INmune Bio Investigational Site
Sherbrooke, J1L 0H8, Canada
-
INmune Bio Investigational Site
Toronto, M3B 2S7, Canada
-
INmune Bio Investigational Site
Toronto, M4G 3E8, Canada
-
INmune Bio Investigational Site
West Vancouver, V7T 1C5, Canada
-
INmune Bio Investigational Site
Brno, 60200, Czechia
-
INmune Bio Investigational Site
Pilsen, 30100, Czechia
-
INmune Bio Investigational Site
Prague, 10000, Czechia
-
INmune Bio Investigational Site
Prague, 16000, Czechia
-
INmune Bio Investigational Site
Rychnov nad Kněžnou, 51601, Czechia
-
INmune Bio Investigational Site
Bron, 69500, France
-
INmune Bio Investigational Site
Nantes, 44800, France
-
INmune Bio Investigational Site
Toulouse, 31059, France
-
INmune Bio Investigational Site
Berlin, 10629, Germany
-
INmune Bio Investigational Site
Chemnitz, 09111, Germany
-
INmune Bio Investigational Site
Bialystok, 15-756, Poland
-
INmune Bio Investigational Site
Bydgoszcz, 85-133, Poland
-
INmune Bio Investigational Site
Wroclaw, 53-659, Poland
-
INmune Bio Investigational Site
Barcelona, 08028, Spain
-
INmune Bio Investigational Site
Barcelona, 08222, Spain
-
INmune Bio Investigational Site
Córdoba, 14004, Spain
-
INmune Bio Investigational Site
Madrid, 28006, Spain
-
INmune Bio Investigational Site
Seville, 41009, Spain
-
INmune Bio Investigational Site
Valencia, 46017, Spain
-
INmune Bio Investigational Site
Valencia, 46026, Spain
-
INmune Bio Investigational Site
Birmingham, B16 8LT, United Kingdom
-
INmune Bio Investigational Site
Bristol, BS32 4SY, United Kingdom
-
INmune Bio Investigational Site
Guildford, GU2 7YD, United Kingdom
-
INmune Bio Investigational Site
London, W1G 9JF, United Kingdom
-
INmune Bio Investigational Site
Motherwell, ML1 4UF, United Kingdom
-
INmune Bio Investigational Site
Plymouth, PL7 8BT, United Kingdom
-
INmune Bio Investigational Site
Winchester, S021 1HU, United Kingdom
Conditions
Explore the condition pages connected to this study.